Back to top
more

Arena Pharmaceuticals, Inc. (ARNA)

(Delayed Data from NSDQ)

$47.60 USD

47.60
308,048

+1.62 (3.52%)

Updated May 3, 2019 04:00 PM ET

After-Market: $47.68 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Analysts Estimate Arena Pharmaceuticals (ARNA) to Report a Decline in Earnings: What to Look Out for

Arena Pharmaceuticals (ARNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Arena Pharmaceuticals (ARNA) Upgraded to Buy: Here's Why

Arena Pharmaceuticals (ARNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Arena Initiates Dosing in Pivotal Colitis Study on Etrasimod

Arena (ARNA) doses first patient in one of the two pivotal late-stage studies evaluating its pipeline candidate, etrasimod in ulcerative colitis indication.

Benjamin Rains headshot

A Company's First Profit Can Mean Big Profits for Investors

Obviously, losing less money than the prior quarter is a positive sign, as it shows growth. Then firms hit a point where they grow and grow and eventually become profitable. These are the stocks that will likely see more demand from new investors...

Why Is Arena Pharmaceuticals (ARNA) Up 9.1% Since Last Earnings Report?

Arena Pharmaceuticals (ARNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

All You Need to Know About Arena Pharmaceuticals (ARNA) Rating Upgrade to Buy

Arena Pharmaceuticals (ARNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Arena Pharmaceuticals' (ARNA) Loss Widens in Q1 But Stock Up

Arena Pharmaceuticals (ARNA) reports loss in the first quarter of 2019 on an adjusted basis. Revenues of $801.1 million include upfront payment of $800 million from United Therapeutics.

United Therapeutics (UTHR) Down Despite Q1 Earnings Beat

United Therapeutics (UTHR) beats estimates on both fronts in the first quarter. However, earnings and revenues decline year over year.

Why Is Arena Pharmaceuticals (ARNA) Down 10.1% Since Last Earnings Report?

Arena Pharmaceuticals (ARNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

United Therapeutics (UTHR) Q4 Earnings & Sales Beat Estimates

United Therapeutics (UTHR) beats estimates for both earnings and sales in the fourth quarter. Stock up.

Arena Pharmaceuticals (ARNA) Beats on Q4 Earnings & Revenues

Arena Pharmaceuticals (ARNA) outpaces earnings estimates in Q4. Also, the top line surpasses the consensus mark. Shares Up.

Why Is Arena Pharmaceuticals (ARNA) Up 8.1% Since Last Earnings Report?

Arena Pharmaceuticals (ARNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

2 New Small Cap ETFs on the Block

Prudential's PGIM launches two actively managed smart-beta ETFs.

Biotech Stock Roundup: GILD's Drug Wins Nod in China, Arena Up On Licensing Deal

Regulatory news and licensing contracts are key highlights in the biotech sector this week.

Arena (ARNA) Out-Licenses Rights to PAH Drug, Stock Up 22%

Arena (ARNA) inks a deal to out-license global rights to its phase III candidate, ralinepag, to United Therapeutics. Shares of the company rally 22% following this news.

Arena Pharmaceuticals (ARNA) Beats on Q3 Earnings and Sales

Arena Pharmaceuticals (ARNA) betters loss estimates in Q3. Also, the top line surpasses the consensus mark.

Analysts Estimate Arena Pharmaceuticals (ARNA) to Report a Decline in Earnings: What to Look Out for

Arena Pharmaceuticals (ARNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Arena (ARNA) Posts Favorable Top-Line Data on Pain Candidate

Arena (ARNA) releases initial optimistic outcomes from a phase IIa study on its pipeline candidate olorinab for treating abdominal pain associated with Crohn's disease.

    Why Is Arena Pharmaceuticals (ARNA) Up 7.4% Since Last Earnings Report?

    Arena Pharmaceuticals (ARNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Arena Pharmaceuticals (ARNA) Q2 Loss Wider Than Expected

      Arena Pharmaceuticals (ARNA) misses second-quarter earnings estimates. Its three key pipeline candidates, ralinepag, etrasimod and Olorinab/APD371, remain in focus.

        What's in the Cards for Arena (ARNA) This Earnings Season?

        With no marketed product, investors will likely focus on Arena's (ARNA) efforts to develop its pipeline on second-quarter earnings call.

          Arena Pharmaceuticals (ARNA) Up 15.1% Since Earnings Report: Can It Continue?

          Arena Pharmaceuticals (ARNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

            Arena Pharmaceuticals (ARNA) Q1 Loss Wider Than Expected

            Arena Pharmaceuticals (ARNA) reports wider-than-expected Q1 loss. Its three key pipeline candidates - ralinepag, etrasimod and Olorinab/APD371 - remain in focus.

              Drug/Biotech Q1 Earnings Lineup on May 8: JAZZ, ARNA & More

              The pharma/biotech industry has witnessed a mixed first-quarter earnings picture so far. Let's see what's in store for some of the smaller players.

                What's in the Cards for Arena (ARNA) This Earnings Season?

                Although Arena's (ARNA) only approved product, Belviq, puts up a dismal show so far, the company's efforts to improve the drug's performance might drive the stock in Q1.